Abstract

Neoantigen profiling represents a groundbreaking approach in the realm of personalized medicine, particularly in oncology. By identifying unique neoantigens generated by tumor-specific mutations, researchers and clinicians can tailor immunotherapies to individual patients, enhancing treatment efficacy and minimizing adverse effects. This article explores the concept of neoantigens, the methodologies employed in neoantigen profiling, and the implications for personalized cancer therapies. Through a thorough literature review, case studies, and expert interviews, we examine the current landscape of neoantigen research, challenges faced in implementation, and the future potential of this innovative strategy. Ultimately, we conclude that neoantigen profiling is a pivotal development in cancer treatment, offering new hope for improved patient outcomes.